To confirm these findings the ability of INPPL1, PIK3R2 and TSC2-deleted PTEN-null BC cells to proliferate in the presence of AZD8186 (PI3Kβi) or capivasertib (AKTi) was tested in competitive and clonogenic growth assays. Here, TSC2 is linked to breast cancer.